Effect of radiofrequency hyperthermia and chemotherapy on primary and secondary hepatic malignancies when used with metronidazole

Frederick L Moffat, R. E. Falk, K. Calhoun, J. C. Langer, Z. Dreznik, L. Makowka, L. E. Rotstein, U. Ambus, V. Howard, A. Campbell, D. Laing, D. Venturi, J. A. Falk

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Hyperthermia is selectively toxic to neoplastic tissue. Since August 1981, 357 patients with incurable tumors in various body areas have been treated with chemotherapy and radiofrequency hyperthermia (RFHT) with adjuvant metronidazole at this center. Of this group, the cases of 102 patients with hepatic tumors are reported here. Patients received one to ten treatment courses, each course consisting of two to five daily RFHT sessions. Systemic temperature rose 0.6 ± 0.3 ° C during treatment, and tumor core temperature (measured by percutaneous transhepatic thermistor) reached 39.5 ± 1.2 dg C in 38 monitored patients. Results have been encouraging; in particular, among 15 patients with newly diagnosed colorectal metastases limited to the liver (and as yet untreated for their secondary disease), there has been objective partial tumor regression in 66.7%. Side effects have been few. Skin burns and subcutaneous fat necrosis were seen in 3.9% and 13.7% of patients, respectively. Tumor temperature is difficult to measure reliably and does not correlate with machine power or tumor response. A phase III trial is currently underway to determine the efficacy of RFHT and chemotherapy for patients with hepatic metastases from colorectal adenocarcinoma.

Original languageEnglish
Pages (from-to)536-542
Number of pages7
JournalSurgery
Volume94
Issue number4
StatePublished - Jan 1 1983
Externally publishedYes

Fingerprint

Metronidazole
Fever
Drug Therapy
Liver
Neoplasms
Temperature
Fat Necrosis
Neoplasm Metastasis
Poisons
Subcutaneous Fat
Burns
Adenocarcinoma
Skin
Therapeutics

ASJC Scopus subject areas

  • Surgery

Cite this

Moffat, F. L., Falk, R. E., Calhoun, K., Langer, J. C., Dreznik, Z., Makowka, L., ... Falk, J. A. (1983). Effect of radiofrequency hyperthermia and chemotherapy on primary and secondary hepatic malignancies when used with metronidazole. Surgery, 94(4), 536-542.

Effect of radiofrequency hyperthermia and chemotherapy on primary and secondary hepatic malignancies when used with metronidazole. / Moffat, Frederick L; Falk, R. E.; Calhoun, K.; Langer, J. C.; Dreznik, Z.; Makowka, L.; Rotstein, L. E.; Ambus, U.; Howard, V.; Campbell, A.; Laing, D.; Venturi, D.; Falk, J. A.

In: Surgery, Vol. 94, No. 4, 01.01.1983, p. 536-542.

Research output: Contribution to journalArticle

Moffat, FL, Falk, RE, Calhoun, K, Langer, JC, Dreznik, Z, Makowka, L, Rotstein, LE, Ambus, U, Howard, V, Campbell, A, Laing, D, Venturi, D & Falk, JA 1983, 'Effect of radiofrequency hyperthermia and chemotherapy on primary and secondary hepatic malignancies when used with metronidazole', Surgery, vol. 94, no. 4, pp. 536-542.
Moffat, Frederick L ; Falk, R. E. ; Calhoun, K. ; Langer, J. C. ; Dreznik, Z. ; Makowka, L. ; Rotstein, L. E. ; Ambus, U. ; Howard, V. ; Campbell, A. ; Laing, D. ; Venturi, D. ; Falk, J. A. / Effect of radiofrequency hyperthermia and chemotherapy on primary and secondary hepatic malignancies when used with metronidazole. In: Surgery. 1983 ; Vol. 94, No. 4. pp. 536-542.
@article{49e4f66bb9624c1d955cb4554fb4eb98,
title = "Effect of radiofrequency hyperthermia and chemotherapy on primary and secondary hepatic malignancies when used with metronidazole",
abstract = "Hyperthermia is selectively toxic to neoplastic tissue. Since August 1981, 357 patients with incurable tumors in various body areas have been treated with chemotherapy and radiofrequency hyperthermia (RFHT) with adjuvant metronidazole at this center. Of this group, the cases of 102 patients with hepatic tumors are reported here. Patients received one to ten treatment courses, each course consisting of two to five daily RFHT sessions. Systemic temperature rose 0.6 ± 0.3 ° C during treatment, and tumor core temperature (measured by percutaneous transhepatic thermistor) reached 39.5 ± 1.2 dg C in 38 monitored patients. Results have been encouraging; in particular, among 15 patients with newly diagnosed colorectal metastases limited to the liver (and as yet untreated for their secondary disease), there has been objective partial tumor regression in 66.7{\%}. Side effects have been few. Skin burns and subcutaneous fat necrosis were seen in 3.9{\%} and 13.7{\%} of patients, respectively. Tumor temperature is difficult to measure reliably and does not correlate with machine power or tumor response. A phase III trial is currently underway to determine the efficacy of RFHT and chemotherapy for patients with hepatic metastases from colorectal adenocarcinoma.",
author = "Moffat, {Frederick L} and Falk, {R. E.} and K. Calhoun and Langer, {J. C.} and Z. Dreznik and L. Makowka and Rotstein, {L. E.} and U. Ambus and V. Howard and A. Campbell and D. Laing and D. Venturi and Falk, {J. A.}",
year = "1983",
month = "1",
day = "1",
language = "English",
volume = "94",
pages = "536--542",
journal = "Surgery (United States)",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Effect of radiofrequency hyperthermia and chemotherapy on primary and secondary hepatic malignancies when used with metronidazole

AU - Moffat, Frederick L

AU - Falk, R. E.

AU - Calhoun, K.

AU - Langer, J. C.

AU - Dreznik, Z.

AU - Makowka, L.

AU - Rotstein, L. E.

AU - Ambus, U.

AU - Howard, V.

AU - Campbell, A.

AU - Laing, D.

AU - Venturi, D.

AU - Falk, J. A.

PY - 1983/1/1

Y1 - 1983/1/1

N2 - Hyperthermia is selectively toxic to neoplastic tissue. Since August 1981, 357 patients with incurable tumors in various body areas have been treated with chemotherapy and radiofrequency hyperthermia (RFHT) with adjuvant metronidazole at this center. Of this group, the cases of 102 patients with hepatic tumors are reported here. Patients received one to ten treatment courses, each course consisting of two to five daily RFHT sessions. Systemic temperature rose 0.6 ± 0.3 ° C during treatment, and tumor core temperature (measured by percutaneous transhepatic thermistor) reached 39.5 ± 1.2 dg C in 38 monitored patients. Results have been encouraging; in particular, among 15 patients with newly diagnosed colorectal metastases limited to the liver (and as yet untreated for their secondary disease), there has been objective partial tumor regression in 66.7%. Side effects have been few. Skin burns and subcutaneous fat necrosis were seen in 3.9% and 13.7% of patients, respectively. Tumor temperature is difficult to measure reliably and does not correlate with machine power or tumor response. A phase III trial is currently underway to determine the efficacy of RFHT and chemotherapy for patients with hepatic metastases from colorectal adenocarcinoma.

AB - Hyperthermia is selectively toxic to neoplastic tissue. Since August 1981, 357 patients with incurable tumors in various body areas have been treated with chemotherapy and radiofrequency hyperthermia (RFHT) with adjuvant metronidazole at this center. Of this group, the cases of 102 patients with hepatic tumors are reported here. Patients received one to ten treatment courses, each course consisting of two to five daily RFHT sessions. Systemic temperature rose 0.6 ± 0.3 ° C during treatment, and tumor core temperature (measured by percutaneous transhepatic thermistor) reached 39.5 ± 1.2 dg C in 38 monitored patients. Results have been encouraging; in particular, among 15 patients with newly diagnosed colorectal metastases limited to the liver (and as yet untreated for their secondary disease), there has been objective partial tumor regression in 66.7%. Side effects have been few. Skin burns and subcutaneous fat necrosis were seen in 3.9% and 13.7% of patients, respectively. Tumor temperature is difficult to measure reliably and does not correlate with machine power or tumor response. A phase III trial is currently underway to determine the efficacy of RFHT and chemotherapy for patients with hepatic metastases from colorectal adenocarcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0020553882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020553882&partnerID=8YFLogxK

M3 - Article

C2 - 6623353

AN - SCOPUS:0020553882

VL - 94

SP - 536

EP - 542

JO - Surgery (United States)

JF - Surgery (United States)

SN - 0039-6060

IS - 4

ER -